Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 36

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 36
---
 31, 2024(in millions)Gross Carrying AmountAccumulated Amortization/ Write-offsGross Carrying AmountAccumulated Amortization/ Write-offsTechnology-related$14,406 $(8,799)$14,327 $(8,605)Patents481 (380)481 (381)Other intangible assets2,406 (1,643)2,380 (1,612)Amortizable intangible assets$17,293 $(10,821)$17,188 $(10,598)    Goodwill$27,240 $(9,900)$26,989 $(9,900)IPR&D$94 $94 Indefinite-lived intangible assets$94 $94 The increase in our balance of goodwill is related primarily to our acquisition of Cortex in the first quarter of 2025. The following represents a roll forward of our goodwill balance by reportable segment:(in millions)MedSurgCardiovascularTotalBalance as of December 31, 2024$7,483 $9,606 $17,089 Goodwill acquired— 205 205 Impact of foreign currency fluctuations and purchase price adjustments17 30 47 Balance as of March 31, 2025$7,500 $9,841 $17,340 Goodwill and Other Intangible Asset Impairments

We did not record any goodwill or other intangible asset impairment charges in the first quarter of 2025 or 2024. We test our goodwill balances in the second quarter of each year as of April 1 for impairment, or more frequently if impairment indicators are present or changes in circumstances suggest an impairment may exist. Refer to Note A – Significant Accounting Policies to our audited financial statements contained in Item 8. Financial Statements and Supplementary Data of our most recent Annual Report on Form 10-K for further discussion of our annual goodwill and intangible asset impairment testing. 

12

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTSDerivative Instruments and Hedging ActivitiesWe address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset